The short answer
Florida passed Senate Bill 1768 in 2025, and it took effect on July 1, 2025, as Chapter 2025-185. It created two matching sections of the Florida Statutes: section 458.3245 for medical doctors (MDs) and section 459.0127 for osteopathic physicians (DOs). Those sections were not changed in 2026, but a 2026 law (Chapter 2026-124, section 461.011) gave podiatric physicians a similar permission for connective tissue, ligament and tendon repair, wound care and pain management, with the same sourcing, notice and consent rules.
Before this law, the only stem cell treatments a Florida doctor could clearly offer were FDA-approved products, treatments inside an FDA-authorized clinical trial, and same-day procedures using a patient's own tissue that fit a federal exception. The 2025 law adds a state permission for some unapproved products, under conditions.
What Florida's 2025 stem cell law allows
A Florida MD or DO may perform stem cell therapy that is not approved by the FDA when all of the following are true:
- The use is in orthopedics, wound care or pain management, and within the physician's scope of practice.
- The cells come from an FDA-registered facility that is certified or accredited by one of four bodies: the National Marrow Donor Program, the World Marrow Donor Association, the Association for the Advancement of Blood and Biotherapies (AABB) or the American Association of Tissue Banks.
- The product contains living cells, shown by a post-thaw viability report for that product lot, sent to the physician before use.
- The facility follows federal manufacturing rules (current good manufacturing practices).
- The supplier contract discloses the accreditation, including who granted it, its scope and its dates, and the facility must tell the physician within 30 days if that changes.
- Every advertisement carries the state notice, and the patient signs a consent form before treatment.
In the law, “stem cell therapy” means treatment with afterbirth placental perinatal stem cells or with human cells, tissues, or cellular or tissue-based products (a term the law copies from federal regulations), used in line with the law's requirements. It encourages the use of adult stem cells, umbilical cord blood and other ethically obtained sources.
What the law does not allow
- Uses outside the three areas. Uses not related to orthopedics, wound care or pain management, such as eye, lung, heart or anti-aging treatments, are not covered.
- Other clinicians. The 2025 law applies only to MDs and DOs, and the 2026 law to podiatric physicians. Nurse practitioners, physician assistants and chiropractors have no such authority of their own.
- Fetal or embryonic cells after an abortion. These are excluded, and willfully using them is a third-degree felony.
- Skipping the safeguards. A physician who breaks the law's conditions can be disciplined by the Board of Medicine or the Board of Osteopathic Medicine.
The notice you will see
Any advertisement for these therapies must carry this statement, in type no smaller than the largest type in the ad:
THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.
That is why the notice appears in large type at the top of this page. If a Florida clinic advertises unapproved stem cell therapy without it, ask why.
What the consent form must cover
Before treatment you must sign a consent form (or your representative, if you are not legally competent to sign), written in language you can understand. It must explain:
- What the treatment is
- That it is not approved by the FDA
- The results you can expect
- Its serious risks, complications and benefits, and those of the alternatives, including no treatment
- That you are encouraged to talk with your primary care provider first
Where bone marrow concentrate fits
In bone marrow aspirate concentrate (BMAC), the most common orthopedic stem cell procedure, your own marrow is drawn from the hip, concentrated and injected in the same visit. The law's definition leaves out minimally manipulated bone marrow used for its normal function, copying federal wording. The FDA treats bone marrow's normal function as forming blood, so it is not settled whether BMAC injected into a joint or tendon falls inside or outside the Florida law.
Clinics offering same-day BMAC usually rely on a federal exception for tissue removed and returned to the same patient during the same surgical procedure, which the FDA reads narrowly. The 2025 law matters most for donor products, such as cells from umbilical cord or placental tissue.
How federal law still applies
A state law cannot change federal law. Under FDA rules, a cell or tissue product can skip FDA approval only if it meets every one of these tests: it is minimally manipulated, it is used for the same basic function it has in the body, it is not combined with another product, and it either has no effect throughout the body and does not depend on living cells, or it comes from the patient or a first- or second-degree blood relative. A separate exception covers tissue removed and put back into the same patient during the same surgical procedure.
A product that fails those tests is regulated as a drug or biologic and needs FDA approval before it can be marketed; until then it may be given only in an FDA-authorized clinical trial. Products sold for their living cells and taken from unrelated donors generally fail the last test. The FDA gave makers of some of these products a period of relaxed enforcement to seek approval, which ended on May 31, 2021.
Lawyers at Holland & Knight have described the Florida law as in direct conflict with federal law and said it is unclear how, or whether, the FDA will enforce against Florida physicians. The FDA can still inspect, send warning letters and go to court.
Florida has seen federal enforcement before
In 2015, three women with macular degeneration paid for injections of fat-derived “stem cells” into both eyes, at the Sunrise, Florida site of a study registered by Bioheart. A 2017 report in the New England Journal of Medicine described what followed: they lost vision within days, and a year later their vision ranged from 20/200 to no light perception at all.
In 2018 the federal government sued US Stem Cell Clinic, a Sunrise area clinic, over its fat-derived product. A federal judge in the Southern District of Florida ruled for the FDA in 2019 and barred the company from offering its fat-derived product, and the U.S. Court of Appeals for the Eleventh Circuit upheld that decision on June 2, 2021. The court found the procedure did not qualify for either federal exception.
Which stem cell products are FDA-approved?
The FDA has approved umbilical cord blood products for disorders of the blood and immune system, Omisirge in 2023 for blood cancers, several gene therapies made from a patient's own blood stem cells (such as Casgevy and Lyfgenia for sickle cell disease), and Ryoncil in December 2024, the first mesenchymal stromal cell therapy, for a complication of stem cell transplant in children. No stem cell product is approved for arthritis, tendon problems, or back, knee or shoulder pain.
Other states with similar laws
Utah passed a stem cell disclosure law in 2024 that lets health care providers use unapproved placental and other cell and tissue products, with no limit on conditions, if they give a near-identical notice. Texas has allowed investigational adult stem cell treatment for severe chronic or terminal illness since 2017. Neither changes federal law.
Questions to ask a Florida clinic
- Is the product my own tissue, such as bone marrow concentrate, or a donor product?
- If it is a donor product, which facility made it, and who accredits that facility?
- Can I see the viability report for the lot you will use?
- Is my condition in orthopedics, wound care or pain management?
- Is the treating clinician an MD, a DO or, for foot and ankle care, a podiatric physician, and will they perform it?
- Can I read the consent form before the day of treatment?
- What does the published evidence show for my diagnosis?
Legal is a lower bar than effective. For the evidence by condition, read stem cell therapy for the shoulder, stem cell injections for back pain and what stem cell therapy costs.
Stem cell evaluations with me in Miami
I am a sports medicine physician, board-certified by the American Board of Family Medicine, and I evaluate joint, tendon and ligament problems in Miami. I will tell you which options fit Florida's rules and are reasonable for your diagnosis, where any cells would come from, and what the evidence shows, and for many patients the right first step is rehab or PRP.
My online consultations are $300 for 30 minutes and $600 for 60 minutes, for patients located in Florida or Tennessee. See stem cell therapy in Miami, or book a consultation.
Frequently asked questions
Is stem cell therapy legal in Florida?
Yes, within limits. Since July 1, 2025, Florida law (sections 458.3245 and 459.0127, Florida Statutes) allows a licensed MD or DO to use stem cell therapies that are not FDA-approved, but only for orthopedics, wound care or pain management, within the physician's scope of practice, with cells from an accredited, FDA-registered facility, a viability report for the product, a signed consent form and a notice in every advertisement.
When did Florida's stem cell law take effect?
July 1, 2025. It was passed as Senate Bill 1768 and signed on June 25, 2025, becoming Chapter 2025-185, Laws of Florida. Those sections were not changed in 2026, but a separate 2026 law (Chapter 2026-124) gave podiatric physicians a similar permission.
Does Florida's law make stem cell therapy legal under federal law?
No. A state law cannot change federal law. The FDA still requires most stem cell products to be approved before they are marketed, and until then they may be given only in an FDA-authorized clinical trial. The FDA can still inspect, send warning letters and go to court. Lawyers at Holland & Knight describe the Florida law as in direct conflict with federal law and say it is unclear how, or whether, the FDA will enforce it.
Can a nurse practitioner or chiropractor offer stem cell therapy in Florida?
The 2025 law applies only to physicians licensed under chapter 458 (MDs) or chapter 459 (DOs). A 2026 law gave podiatric physicians (DPMs) a similar permission for foot and ankle care. Neither gives nurse practitioners, physician assistants or chiropractors any authority of their own to offer unapproved stem cell therapy.
What conditions can be treated with stem cells under Florida law?
Only uses related to orthopedics, wound care or pain management, and only within the physician's scope of practice. Uses not related to those three areas, such as eye, lung, heart or anti-aging treatments, are not covered.
Is bone marrow aspirate concentrate covered by the Florida law?
Not clearly. The law's definition leaves out minimally manipulated bone marrow used for its normal function, copying federal wording, but the FDA treats bone marrow's normal function as forming blood. So it is not settled whether same-day bone marrow aspirate concentrate (BMAC) injected into a joint or tendon falls inside or outside the Florida law. Clinics offering same-day BMAC usually rely on a federal exception for tissue removed and returned in the same procedure, which the FDA reads narrowly.
What does the Florida stem cell notice say?
"THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy." It must appear in any advertisement, in type at least as large as the largest type in the ad.
Are any stem cell products FDA-approved?
Yes, but none for orthopedic use. The FDA has approved umbilical cord blood products for blood and immune disorders, Omisirge (2023) for blood cancers, several gene therapies made from a patient's own blood stem cells (such as Casgevy and Lyfgenia for sickle cell disease), and Ryoncil (December 2024), the first mesenchymal stromal cell therapy, for a complication of stem cell transplant in children. No stem cell product is approved for arthritis, tendon, back, knee or shoulder pain.
Sources
- Florida Statutes s. 458.3245, Stem cell therapy (physicians, MD)
- Florida Statutes s. 459.0127, Stem cell therapy (osteopathic physicians, DO)
- Florida Statutes s. 461.011, Cellular and tissue-based products (podiatric physicians)
- Florida Senate: SB 1092 (2026), Chapter 2026-124
- Laws of Florida: Chapter 2025-185
- Florida Senate: SB 1768 (2025), Stem Cell Therapy
- 21 CFR 1271.10: Criteria for regulation solely under section 361 of the PHS Act
- 21 CFR 1271.15: Exceptions, including the same surgical procedure exception
- FDA: Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use (guidance)
- FDA: Same surgical procedure exception under 21 CFR 1271.15(b): questions and answers (guidance)
- FDA: Questions and answers on the end of the compliance and enforcement policy for HCT/Ps (May 31, 2021)
- FDA: Approved cellular and gene therapy products
- FDA: FDA approves first mesenchymal stromal cell therapy (Ryoncil), December 2024
- FDA: Important patient and consumer information about regenerative medicine therapies
- Holland & Knight: New Florida law attempts to provide leeway for certain stem cell treatments, August 18, 2025
- United States v. US Stem Cell Clinic, LLC, 998 F.3d 1302 (11th Cir. 2021)
- U.S. Attorney, Southern District of Florida: Florida company barred from using experimental stem cell drugs on patients, 2019
- Kuriyan AE et al. Vision loss after intravitreal injection of autologous "stem cells" for AMD. N Engl J Med, 2017
- ClinicalTrials.gov NCT02024269: Study to assess the safety and effects of cells injected intravitreal in dry macular degeneration (Bioheart, Sunrise, Florida)
- Utah Code 58-1-512: Stem cell disclosure
- Texas Legislature: HB 810 (2017), bill analysis
